Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JW2202 inhalation powder in COPD
CTR20254751Phase 3Active
- Sponsor
- Shandong Jianwei Pharmaceutical
- Start
- Feb 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of indacaterol acetate + glycopyrronium bromide + mometasone furoate in chronic obstructive pulmonary disease (COPD), chronic bronchitis (CB), emphysema, sponsored by Shandong Jianwei Pharmaceutical. Started Feb 2026; status: active.
02
Drugs
indacaterol acetate + glycopyrronium bromide + mometasone furoate
03
Conditions
chronic obstructive pulmonary disease (COPD)chronic bronchitis (CB)emphysema
Beyond the preview
Go deeper on CTR20254751.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254751.